11/13
12:53 pm
nmra
Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
11/13
08:06 am
nmra
Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Medium
Report
Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
11/12
07:00 am
nmra
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
High
Report
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/6
07:00 am
nmra
Neumora Therapeutics to Participate in Upcoming Conferences in November
High
Report
Neumora Therapeutics to Participate in Upcoming Conferences in November
11/5
07:00 am
nmra
Neumora Therapeutics, Inc. (NASDAQ: NMRA) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $15.00 price target on the stock, down previously from $18.00.
Medium
Report
Neumora Therapeutics, Inc. (NASDAQ: NMRA) was downgraded by analysts at JPMorgan Chase & Co. from an "overweight" rating to a "neutral" rating. They now have a $15.00 price target on the stock, down previously from $18.00.
10/29
07:00 am
nmra
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
Low
Report
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
10/18
08:33 am
nmra
Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Low
Report
Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
10/16
02:59 am
nmra
Neumora Therapeutics: A Story Of A Class II Biotech [Seeking Alpha]
Medium
Report
Neumora Therapeutics: A Story Of A Class II Biotech [Seeking Alpha]
10/1
08:59 am
nmra
Neumora Therapeutics (NASDAQ:NMRA) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Low
Report
Neumora Therapeutics (NASDAQ:NMRA) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
10/1
07:57 am
nmra
Neumora Therapeutics, Inc. (NASDAQ: NMRA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
Low
Report
Neumora Therapeutics, Inc. (NASDAQ: NMRA) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $30.00 price target on the stock.
9/12
02:15 pm
nmra
Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Low
Report
Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
9/4
10:05 am
nmra
Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $29.00 price target on the stock.
Medium
Report
Neumora Therapeutics, Inc. (NASDAQ: NMRA) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $29.00 price target on the stock.